Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: Bayesian evidence synthesis with target trial emulation

Abstract

'David J.A. Jenkins' 'Reynaldo Martina' 'Kimme L Hyrich' 'Keith R. Abrams'] Study design and setting: We use data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) to supplement RCT evidence obtained from the literature, by emulating target trials of treatment sequences to estimate treatment effects in each line of therapy. Treatment effects estimates from the target trials inform a bivariate network meta-analysis (NMA) of first and second-line treatments.